+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers



Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers



Pharmacology 99(1-2): 84-88



Attention deficit hyperactivity disorder (ADHD) is frequently associated with other psychiatric pathologies. Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX). Designed as an open-label, non-randomized clinical trial, the study included 2 periods. In period 1 (reference), each subject received ATX 25 mg (single-dose), whereas in period 2 (test), all subjects were given a combination of ATX 25 mg + FVX 100 mg, following a 6-day pretreatment regimen with the enzymatic inhibitor. Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide. The results revealed significant differences between the study periods for Cmax, AUC0-t and AUC0-∞ values corresponding to ATX and its metabolite. Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor. FVX had a modest effect on the pharmacokinetics of ATX and 4-hydroxyatomoxetine-O-glucuronide. The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057817069

Download citation: RISBibTeXText

PMID: 27816979

DOI: 10.1159/000452223


Related references

Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. Journal of Pharmacy and Pharmaceutical Sciences 19(2): 198-207, 2017

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology 69(4): 835-842, 2013

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. Journal of Clinical Pharmacology 41(2): 217-223, 2001

Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clinical Drug Investigation 18(2): 141-150, 1999

A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 37, 2003

Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. International Journal of Clinical Pharmacology and Therapeutics 49(12): 756-764, 2011

Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. Pharmacology 98(3-4): 190-198, 2016

Assessment of the pharmacokinetic , pharmacodynamic interaction potential between posaconazole and glipizide in healthy volunteers. Clinical Pharmacology & Therapeutics 73(2): P45, 2003

Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 47(9): 564-569, 2009

Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. European Journal of Clinical Pharmacology 32(4): 389-393, 1987

Evaluation of the pharmacokinetic interaction between phenytoin and nelfinavir in healthy volunteers at steady state. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 14, 2000

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical Drug Investigation 37(3): 303-309, 2017

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. Journal of Clinical Pharmacology 46(10): 1195-1203, 2006

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 36(1): 17-24, 2011

Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharmaceutical Research 7(11): 1172-1176, 1990